Description
Eronib 150 MG (Erlotinib)
Product Features:
| Product Name | : Eronib |
| Generic Name | : Erlotinib |
| Manufacturer | : Healthcare Pharma Ltd. |
| Indication | : Lung & Pancreatic Cancer |
| Formulation | : Tablet |
| Strength | : 150 mg |
| Quantity | : 28 Tablets |
| Storage | : Below 30°C |
| Registrations | : Export Only |
UNDERSTANDING ERONIB 150 MG
Cancer is still one of the most difficult diseases to treat, and conventional therapies such as chemotherapy and radiation can have considerable side effects. But with progress in medical science, there are new drugs called targeted therapies that bring targeted approaches to fight against cancer. Eronib 150 MG is one such medication, with Erlotinib as its active ingredient. In this article, we will discuss the applications, mechanism of action, advantages, and side effects of Eronib 150 MG, delving into its significance in contemporary cancer treatment.
WHAT IS ERONIB 150 MG?
Eronib 150 MG contains Erlotinib a tyrosine kinase inhibitor (TKI) in an oral formulation. It specifically works to bind to and block the action of the epidermal growth factor receptor (EGFR), a protein that is expressed on the surface of some cancer cells. EGFR is essential for cellular growth, division, and survival. In certain cancers, including non-small cell lung cancer (NSCLC) and pancreatic cancer, EGFR is overactive and tumor growth occurs uncontrollably. Erlotinib is a small molecule EGFR blocker, which prevents EGFR from functioning, thereby slowing or stopping the evolution of these tumors.
INDICATIONS AND USES
Eronib 150 MG is mainly used to treat:
Non-Small Cell Lung Cancer (NSCLC): First-line treatment for patients with advanced NSCLC with specific EGFR mutations. It can be optioned as a maintenance therapy or where other options have failed.
Pancreatic Cancer: Given in conjunction with gemcitabine for advanced or metastatic disease.
Before beginning treatment with Eronib, genetic testing is usually done to confirm that the cancer cells have EGFR mutations that would trigger the effectiveness of the drug.
HOW DOSE ERONIB 150 MG WORK?
Eronib 150 MG inhibits the EGFR tyrosine kinase selectively, inhibiting the cell-signaling pathway responsible for cancer cell growth and survival. Blocking this receptor with Erlotinib inhibits the activation of signaling pathways that are responsible for tumor cell proliferation and survival, thus halting or slowing tumor cell development.
DOSAGE AND ADMINISTRATION
Standard Dose: The usual recommended dose for NSCLC and pancreatic cancer is 150 mg orally, once daily, at least one hour before or two hours after a meal.
Time frame: Treatment continues while the patient derives benefit from the therapy or until unacceptable toxicity.
Dosage Modification: May need to be adjusted due to side effects or other drug interactions.
BENEFITS OF ERONIB 150 MG
Targeted Therapy: Eronib provides a targetable therapy by specifically targeting cancer cells that have certain genetic alterations, thus leaving healthy cells unharmed.
Improved Survival Rates: Clinical trials have demonstrated that use of erlotinib can greatly prolong progression-free survival and overall survival in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
Oral Administration: Eronib can be administered orally, offering a convenient alternative to intravenous therapies for patients.
POTENTIAL SIDE EFFECTS
Eronib 150 MG, like all medicines, can cause side effects, but many people have no side effects or only have minor side effects. Common side effects include:
- Skin Rash: An acne-like rash that typically accompanies infection, and commonly affects the face and upper body.
- Diarrhea: Mild to moderate gastrointestinal disturbances.
- Fatigue: A sense of tiredness or kinetic weakness.
- Loss of Appetite Anorexia: No appetite.
- Nausea and Vomiting: Minor gastrointestinal upset.
More serious side effects, such as liver toxicity, severe diarrhea, or interstitial lung disease (ILD), are also possible, but they are rare. Patients must alert their physician instantly of any unusual indications.
CAUTIONS AND CONSIDERATIONS
Smoking: Overall effectiveness of Erlotinib is decreased, so it is strongly advised that patients cease smoking.
Liver and Kidney Impairment: Patients that exhibit hepatic or renal dysfunction may need adjustments to this dosage.
Interstitial Lung Disease (ILD): A rare but serious side effect that requires immediate medical attention.
Pregnancy and Breastfeeding: Not recommended as it can harm the fetus or infant.
Moreover, Eronib can interact with other medications, including blood thinners, antifungals, and certain antibiotics. All medications and supplements should be discussed with a health care provider to avoid potential interactions.
DRUG INTERACTIONS:
CYP3A4 inhibitors: Eronib is primarily substrate of CYP3A4. Increased levels of Eronib AUC (67%) were observed after co-treatment with the strong CYP3A4 inhibitor ketoconazole. Co-administration of Eronib with Ciprofloxacin, a dual CYP3A4 and CYP1A2 inhibitor, increased Eronib AUC and Cmax by 39% and 17%.
Inducers of CYP3A4: Co-administration of the CYP3A4 inducer Rifampicin for 7–11 days before the administration of Eronib led to a 58% to 80% reduction in Eronib AUC. Changes to the dose are advised.
Gastric pH Modifying agents: Administering Eronib together with omeprazole resulted in a 46% decrease of Eronib AUC; administering Eronib with Ranitidine 300 mg resulted in a 33 % decrease of Eronib AUC.
Anticoagulants: Decreased efficacy of coumarin-derived anticoagulants (eg, warfarin) due to increased INR and bleeding ADRs
STORAGE AND HANDLING:
Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and light. Keep out of reach of children.
SUPPLIED PARTNER
All the intravenous drugs are delivered with guaranteed lowest price from Emergency Drug. They are also partnered with trustworthy manufacturers further maintaining a high standard for their medicines. With a customer-first approach they are your Trusted Partner in all things Pharmaceuticals.
CONCLUSION
Eronib 150 MG (Erlotinib) is one of the most advanced(s) targeted cancer therapies available in the fields. And by selectively hitting EGFR-mutated cancer cells, it may provide more effective and less toxic treatment for patients with non-small cell lung cancer and pancreatic cancer. Side effects may occur, but the overall benefits of better survival rates and quality of life make Eronib a powerful weapon in the war on cancer. Eronibiertes is a powerful medication, and as with any powerful medication, it is important to remember that it should not be used without the guidance of a qualified healthcare professional.
Eronib 150 MG is a source of hope and a new ray of hope in the fight against cancer for patients and their family. With ongoing research, targeted therapies such as Erlotinib may prove to play a central role in revolutionizing the therapeutic armamentarium in cancer care.
Disclaimer: This article is for informational purposes only and should not replace professional medical advice. Always consult a healthcare provider for diagnosis and treatment options tailored to your specific condition.
Reviews
There are no reviews yet.